$4.44
4.52% today
Nasdaq, Dec 30, 10:00 pm CET
ISIN
US92859E1082
Symbol
VVOS

Vivos Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Vivos Therapeutics Inc Classifications & Recommendation:

Buy
100%

Vivos Therapeutics Inc Price Target

Target Price $6.30
Price $4.65
Potential
Number of Estimates 2
2 Analysts have issued a price target Vivos Therapeutics Inc 2025 . The average Vivos Therapeutics Inc target price is $6.30. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend Vivos Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vivos Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Vivos Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 13.80 15.20
13.86% 10.16%
EBITDA Margin -120.87% -72.36%
20.51% 40.13%

2 Analysts have issued a sales forecast Vivos Therapeutics Inc 2024 . The average Vivos Therapeutics Inc sales estimate is

$15.2m
Unlock
. This is
4.27% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$15.2m 4.28%
Unlock
, the lowest is
$15.2m 4.25%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $13.8m 13.86%
2024
$15.2m 10.16%
Unlock
2025
$19.2m 26.02%
Unlock

1 Analyst has issued an EBITDA forecast Vivos Therapeutics Inc 2024 . The average Vivos Therapeutics Inc EBITDA estimate is

$-11.0m
Unlock
. This is
8.79% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-11.0m 8.79%
Unlock
, the lowest is
$-11.0m 8.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-16.7m 31.53%
2024
$-11.0m 34.05%
Unlock
2025
$-8.8m 20.00%
Unlock

EBITDA Margin

2023 -120.87% 20.51%
2024
-72.36% 40.13%
Unlock
2025
-45.94% 36.51%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
EV/Sales 1.17

Based on analysts' sales estimates for 2024, the Vivos Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.22 8.93%
2024
1.17 3.97%
Unlock
2025
0.93 20.65%
Unlock

P/S ratio

Current 1.54 48.15%
2024
1.48 4.09%
Unlock
2025
1.17 20.65%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today